Researchers had found in a new study that sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 ...

The researchers found that both SGLT2 inhibitors and GLP-1 agonists were associated with a lower risk of major cardiovascular events, but the drug effects varied with the patients’ age.

Less than 5% of hospitalized adults with type 2 diabetes received an SGLT2 inhibitor or GLP-1 before being discharged, ...

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

GLP-1 receptor agonists conferred greater HbA1c reductions in older adults than younger adults. Older adults had a lower risk for major adverse CV events than younger adults with SGLT2 inhibitors.

UK: A recent consensus statement from leading UK medical organizations—including the Association of Anaesthetists, the ...

• Glucagon-like peptide 1 receptor agonists (GLP-1) (medicines used to lower blood glucose) probably reduce the risk of death due to any cause but may have little or no death due to a heart attack in ...

and colleagues reviewed the literature to examine whether age or sex is associated with differences in the efficacy of sodium ...

A network meta-analysis reveals age-dependent variations in efficacy of popular diabetes drugs, with SGLT2 inhibitors showing ...

Research reveals GLP-1 and SGLT-2 medications may lower COPD exacerbation risk in diabetes, offering new hope for dual ...

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) and SGLT-2 inhibitors, commonly used for blood sugar control, also offer benefits such as weight loss and reduced inflammation. Although ...

The researchers found that both SGLT2 inhibitors and GLP-1 agonists were associated with a lower risk of major cardiovascular events, but the drug effects varied with the patients’ age. Cheng-Han Chen ...